The European Medicines Agency Review of Carfilzomib for the Treatment of Adult Patients with Multiple Myeloma Who Have Received at Least One Prior Therapy

On November 19, 2015, a marketing authorization valid through the European Union was issued for carfilzomib in combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma (MM) who have received at least one prior therapy. In a phase III trial in patients...

وصف كامل

محفوظ في:
التفاصيل البيبلوغرافية
الحاوية / القاعدة:Oncologist
المؤلفون الرئيسيون: Tzogani, Kyriaki, Camarero Jiménez, Jorge, Garcia, Isabel, Sancho‐López, Arantxa, Martin, Marc, Moreau, Alexandre, Demolis, Pierre, Salmonson, Tomas, Bergh, Jonas, Laane, Edward, Ludwig, Heinz, Gisselbrecht, Christian, Pignatti, Francesco
التنسيق: Artigo
اللغة:Inglês
منشور في: AlphaMed Press 2017
الموضوعات:
Regulatory Issues: EMA
الوصول للمادة أونلاين:https://ncbi.nlm.nih.gov/pmc/articles/PMC5679835/
https://ncbi.nlm.nih.gov/pubmed/28935772
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2017-0184
الوسوم: إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

مواد مشابهة